ym 529 has been researched along with thalidomide in 1 studies
| Studies (ym 529) | Trials (ym 529) | Recent Studies (post-2010) (ym 529) | Studies (thalidomide) | Trials (thalidomide) | Recent Studies (post-2010) (thalidomide) |
|---|---|---|---|---|---|
| 140 | 23 | 71 | 9,789 | 1,385 | 4,342 |
| Protein | Taxonomy | ym 529 (IC50) | thalidomide (IC50) |
|---|---|---|---|
| Cereblon isoform 4 | Magnetospirillum gryphiswaldense | 7.8 | |
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 0.37 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 0.5 | |
| DNA damage-binding protein 1 | Homo sapiens (human) | 1.38 | |
| Protein cereblon | Homo sapiens (human) | 1.38 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Otsuki, T; Sugihara, T; Wada, H; Yamada, O; Yata, K; Yawata, Y | 1 |
1 other study(ies) available for ym 529 and thalidomide
| Article | Year |
|---|---|
Synergistic growth inhibition of YM529 with biologic response modifiers (BRMs) in myeloma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Diphosphonates; Drug Synergism; Humans; Imidazoles; Interferon-alpha; Interphase; Multiple Myeloma; RNA; Thalidomide; Tretinoin; Tumor Cells, Cultured | 2002 |